{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:05:13Z","timestamp":1789693513252,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,13]],"date-time":"2027-08-13T00:00:00Z","timestamp":1818115200000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12 HD000849"],"award-info":[{"award-number":["K12 HD000849"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002389-07"],"award-info":[{"award-number":["UL1TR002389-07"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002956","name":"Foundation for Women's Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA014599"],"award-info":[{"award-number":["P30CA014599"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ygyno.2026.08.005","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:24:44Z","timestamp":1786627484000},"page":"134-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Feedback activation of MAPK-ERK1\/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers"],"prefix":"10.1016","volume":"212","author":[{"given":"Anh Q.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Bednarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Al-Sawalha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Nagele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Moroney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julieta B.","family":"Lastra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subin","family":"Myong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyedmohsen","family":"Hosseinibarkooie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao Huan Samuel","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine C.","family":"Kurnit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Diane","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gini F.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridevi","family":"Challa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2026.08.005_bb0005","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.ygyno.2026.08.005_bb0010","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/AOG.0000000000004676","article-title":"The changing landscape of gynecologic cancer mortality in the United States","volume":"139","author":"Giaquinto","year":"2022","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.08.005_bb0015","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/COC.0b013e31829a2974","article-title":"Advances in the management of recurrent endometrial cancer","volume":"38","author":"Bradford","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.005_bb0020","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1093\/annonc\/12.suppl_1.S9","article-title":"The role of overexpressed HER2 in transformation","volume":"12","author":"Neve","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.005_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2023.11.021","article-title":"Molecular landscape of ERBB2\/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions","volume":"180","author":"Nasioudis","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2026.08.005_bb0030","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/1078-0432.CCR-09-0636","article-title":"Resistance to trastuzumab in breast cancer","volume":"15","author":"Pohlmann","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.005_bb0035","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ygyno.2026.08.005_bb0040","author":"Daiichi Sankyo"},{"issue":"16","key":"10.1016\/j.ygyno.2026.08.005_bb0045","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-20-4557","article-title":"FDA approval summary: fam-trastuzumab deruxtecan-Nxki for the treatment of unresectable or metastatic HER2-positive breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.ygyno.2026.08.005_bb0050","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ygyno.2026.08.005_bb0055","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab Deruxtecan for human epidermal growth factor receptor 2\u2013expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.005_bb0060","doi-asserted-by":"crossref","unstructured":"F. Meric-Bernstam, V. Makker, A. Oaknin, D.-Y. Oh, S. Banerjee, A. Gonz\u00e1lez-Mart\u00edn, et al., Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol., 2023. 42(1): p. 47\u201358.","DOI":"10.1200\/JCO.23.02005"},{"key":"10.1016\/j.ygyno.2026.08.005_bb0065","author":"Administration, U.S.F.D"},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.005_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010154","article-title":"Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs","volume":"14","author":"D\u00edaz-Rodr\u00edguez","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.005_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-021-00265-1","article-title":"HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now","volume":"7","author":"Schlam","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"33","key":"10.1016\/j.ygyno.2026.08.005_bb0080","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1038\/s41388-018-0251-y","article-title":"Notch-1-PTEN-ERK1\/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival","volume":"37","author":"Baker","year":"2018","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.ygyno.2026.08.005_bb0085","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ygyno.2026.08.005_bb0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s43856-021-00019-x","article-title":"Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis","volume":"1","author":"Berg","year":"2021","journal-title":"Commun. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2026.08.005_bb0095","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2422694122","article-title":"Uterine organoids reveal insights into epithelial specification and plasticity in development and disease","volume":"122","author":"Rizo","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.005_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053518","article-title":"AKT signaling as a novel factor associated with in vitro resistance of human AML to Gemtuzumab Ozogamicin","volume":"8","author":"Rosen","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ygyno.2026.08.005_bb0105","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/annonc\/12.suppl_1.S35","article-title":"Mechanism of action of anti-H ER2 monoclonal antibodies","volume":"12","author":"Albanell","year":"2001","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.08.005_bb0110","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.005_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-46811-w","article-title":"Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer","volume":"15","author":"Bulle","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ygyno.2026.08.005_bb0120","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4143\/crt.2018.526","article-title":"Therapeutic targeting of the DNA damage response using an ATR inhibitor in biliary tract cancer","volume":"51","author":"Nam","year":"2019","journal-title":"Cancer Res. Treat."},{"issue":"32","key":"10.1016\/j.ygyno.2026.08.005_bb0125","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1038\/sj.onc.1210268","article-title":"Irradiation-induced G2\/M checkpoint response requires ERK1\/2 activation","volume":"26","author":"Yan","year":"2007","journal-title":"Oncogene"},{"issue":"17","key":"10.1016\/j.ygyno.2026.08.005_bb0130","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41388-017-0108-9","article-title":"Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2\/xL in HER2-positive breast cancer","volume":"37","author":"Saatci","year":"2018","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.ygyno.2026.08.005_bb0135","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1158\/1078-0432.CCR-17-0696","article-title":"Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer","volume":"23","author":"Sabbaghi","year":"2017","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:41:30Z","timestamp":1789692090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826020950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S0090825826020950"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feedback activation of MAPK-ERK1\/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}